These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 9030661)

  • 1. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease.
    Gicheru MM; Olobo JO; Anjili CO
    Exp Parasitol; 1997 Feb; 85(2):109-16. PubMed ID: 9030661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of antibodies and cell mediated immune response against Leishmania major in feral nonhuman primates from Kenya.
    Gicheru MM; Jeneby MM; Macharia JC; Carlsson HE; Suleman MA
    Acta Trop; 2009 Feb; 109(2):136-40. PubMed ID: 18983806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral leishmaniasis in vervet monkeys: immunological responses during asymptomatic infections.
    Gicheru MM; Olobo JO; Kariuki TM; Adhiambo C
    Scand J Immunol; 1995 Feb; 41(2):202-8. PubMed ID: 7863267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
    Masina S; M Gicheru M; Demotz SO; Fasel NJ
    J Infect Dis; 2003 Oct; 188(8):1250-7. PubMed ID: 14551897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63).
    Olobo JO; Anjili CO; Gicheru MM; Mbati PA; Kariuki TM; Githure JI; Koech DK; McMaster WR
    Vet Parasitol; 1995 Dec; 60(3-4):199-212. PubMed ID: 8747903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of anti-Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae).
    Anjili C; Langat B; Ngumbi P; Mbati PA; Githure J; Tonui WK
    East Afr Med J; 2006 Feb; 83(2):72-8. PubMed ID: 16708877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative susceptibility of African green monkeys (Cercopithecus aethiops) to experimental infection with Leishmania leishmania donovani and Leishmania leishmania infantum.
    Binhazim AA; Shin SS; Chapman WL; Olobo J
    Lab Anim Sci; 1993 Feb; 43(1):37-47. PubMed ID: 8459677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S; Vasishta RK; Arora SK
    Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An experimental vaccine providing heterologous protection for Leishmania species in murine model.
    Bebars MA; el Serougi AO; Makled KM; Mikhael EM; Abou Gamra MM; el Sherbiny M; Mohareb AW; Mohammed EA
    J Egypt Soc Parasitol; 2000 Apr; 30(1):137-56. PubMed ID: 10786026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC
    J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.